Rosiglitazone Quantification In Rat Plasma Using High Performance Liquid Chromatography With Mass Spectrometric Detection And Its Application To Pre-Clinical Pharmacokinetic Studies

References

1. 1.↵
   1. Young P. W.,
   2. Buckle D. R.,
   3. Cantello B. C.

   Identification of high-affinity binding sites for the insulin sensitizer-rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J. Pharmacol. Exp. Ther. 1998, 284 (2), 751–759.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
2. 2.↵
   1. Patel J.,
   2. Miller E.,
   3. Patwardhan R.

   Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients, Diabetes. 1998, 47 (Suppl. 1), A17.

   OpenUrlGoogle Scholar
3. 3.↵
   1. Lehmann J. M.,
   2. Moore L. B.,
   3. Smith-Oliver T. A.

   An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. 1995, 270 (22), 12953–12956.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
4. 4.↵
   1. Willson T. M.,
   2. Cobb J. E.,
   3. Cowan D. J.,
   4. Wiethe R. W.,
   5. Correa I. D.,
   6. Prakash S. R.,
   7. Beck K. D.,
   8. Moore L. B.,
   9. Kliewer S. A.,
   10. Lehmann J. M.

   The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 1996, 39 (3), 665–668.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
5. 5.↵
   1. Gaal L. V.,
   2. Scheen A. J.

   Are all the glitazones same? Diabetes Metab. Res. Rev. 2002, 18 (Supp 2), S4.

   OpenUrlGoogle Scholar
6. 6.↵
   1. Miller A. K.,
   2. Inglis A. L.,
   3. Thompson K.,
   4. Davie C. C.,
   5. Schenker S.,
   6. Blum R.,
   7. Jorkasky D.,
   8. Freed M. I.

   Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG). Clin. Pharmacol. Ther. 1999, 65, 186.

   OpenUrlGoogle Scholar
7. 7.↵
   1. Freed M. I.,
   2. Allen A.,
   3. Jorkasky D. K.,
   4. DiCicco R. A.

   Systemic exposure to rosiglitazone is unaltered by food. Eur. J. Clin. Pharmacol. 1999, 55 (1), 53–56.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
8. 8.↵
   1. Cox P. J.,
   2. Ryan D. A.,
   3. Hollis F. J.,
   4. Harris A. M.,
   5. Miller A. K.,
   6. Vousden M.,
   7. Cowley H.

   Absorption, disposition and metabolism of rosiglitazone, a potent thaizolidinedione insulin sensitizer in humans. Drug Metab. Dispos. 2000, 28 (7), 772–780.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
9. 9.↵
   1. Radhakrishna T.,
   2. Satyanarayana J.,
   3. Satyanarayana A.

   LC determination of rosiglitazone in bulk and pharmaceutical formulation. J. Pharm. Biomed. Anal. 2002, 29 (5), 873–880.

   OpenUrlPubMedGoogle Scholar
10. 10.↵
    1. Gomes P.,
    2. Sippel J.,
    3. Jablonski A.,
    4. Steppe M.

    Determination of rosiglitazone in coated tablets by MEKC and HPLC methods. J. Pharm. Biomed. Anal. 2004, 36 (4), 909–913.

    OpenUrlPubMedGoogle Scholar
11. 11.↵
    1. Kolte B. L.,
    2. Raut B. B.,
    3. Deo A. A.,
    4. Bagool M. A.,
    5. Shinde D. B.

    Simultaneous determination of metformin in combination with rosiglitazone in pharmaceutical formulations. J. Chromatogr. Sci. 2004, 42 (2), 70–73.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
12. 12.↵
    1. Kolte B. L.,
    2. Raut B. B.,
    3. Deo A. A.,
    4. Bagool M. A.,
    5. Shinde D. B.

    Liquid chromatographic method for the determination of rosiglitazone in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 788 (1), 37–44.

    OpenUrlPubMedGoogle Scholar
13. 13.↵
    1. Gaffney M. H.,
    2. Allen G. D.,
    3. Abbott R. W.

    Determination rosiglitazone in plasma by HPLC with fluorescence detector. Methodol. Surv. Bioanal. Drugs. 1994, 23, 251.

    OpenUrlGoogle Scholar
14. 14.↵
    1. Muxlow A. M.,
    2. Fowles S.,
    3. Russell P.

    Automated high performance liquid chromatographic method for the determination of rosiglitazone in plasma. J. Chromatogr. B Biomed. Sci. Appl. 2001, 752 (1), 77–84.

    OpenUrlCrossRefPubMedGoogle Scholar
15. 15.↵
    1. Mamidi R. N.,
    2. Benjamin B.,
    3. Ramesh M.,
    4. Srinivas N. R.

    Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. Biomed. Chromatogr. 2003, 17 (6), 417–420.

    OpenUrlCrossRefPubMedGoogle Scholar
16. 16.↵
    1. Kim K. A.,
    2. Park J. Y.

    Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. Biomed. Chromatogr. 2004, 18 (8), 613–615.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
17. 17.↵
    1. Hruska M. W.,
    2. Frye R. F.

    Simplified method for the determination of rosiglitazone in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2004, 803 (2), 317–320.

    OpenUrlPubMedGoogle Scholar
18. 18.↵
    1. Lin Z. J.,
    2. Desai-Krieger D.,
    3. Shum L.

    Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography–tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2004, 801 (2), 265–272.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
19. 19.↵
    1. Ho E. N.,
    2. Yiu C. H.,
    3. Wan S. M.,
    4. Stewart B. D.,
    5. Watkins K. L.

    Detection of anti-diabetics in equine plasma and urine by liquid chromatography–tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 811 (1), 65–73.

    OpenUrlPubMedWeb of ScienceGoogle Scholar
20. 20.↵
    1. Soglia J. R.,
    2. Harriman S. P.,
    3. Zhao S.

    The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography–micro-electrospray ionization–tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J. Pharm. Biomed. Anal. 2004, 36 (1), 105–116.

    OpenUrlCrossRefPubMedGoogle Scholar
21. 21.↵
    International Conference on Harmonization, Topic Q2B, Validation of Analytical Methods: Methodology. Third International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Yokohama, Japan, 1997.

    Google Scholar
22. 22.↵
    U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. http://www.fda.gov/cder/guidance/index.htm (2001).

    Google Scholar
23. 23.↵
    U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Guidance for Industry. Animal Models—Essential Elements to Address Efficacy Under the Animal Rule, 2009.

    Google Scholar
24. 24.↵
    Committee for the Purpose of Control and Supervision of Experiments on Animals—CPCSEA. Guidelines for the laboratory animal facility. Indian J. Pharmacol. 2003, 35 (4), 257–274.

    OpenUrlGoogle Scholar